Management Strategies and Existing Gaps in Alopecia Areata: Insights from Malaysia
By
Azura Mohd Affandi
Adawiyah Jamil
Noor Zalmy Azizan
Felix Boon-Bin Yap
Kin Fon Leong
Agnes Yoke Hui Heng
Siti Nuraihan
Wooi Chiang Tan
Latha Selvarajah
Teeba Raja
Evelyn Wen Yee Yap
Peter Wee Beng Ch'ng
Tze Yuen Teoh
Mei Ying Tey
September 21, 2026
Clinical Scorecard: Management Strategies and Existing Gaps in Alopecia Areata: Insights from Malaysia
At a Glance
Category Detail
Condition Alopecia Areata Key Mechanisms Chronic autoimmune disorder causing nonscarring hair loss due to immune cell attack on hair follicles. Target Population Individuals with alopecia areata, particularly children and adolescents. Care Setting Primary care settings, including government health clinics and private practices.
Key Highlights
Alopecia areata affects approximately 1 in 1000 individuals with a lifetime risk of about 2%. Common comorbidities include vitiligo, lupus, psoriasis, and psychiatric disorders. Initial management may involve topical corticosteroids, with referrals to dermatology for severe cases. Guideline-Based Recommendations
Diagnosis
Diagnosis may require referral to dermatology for confirmation and evaluation of disease activity. Management
Topical corticosteroids are commonly used for mild, localized hair loss. Monitoring & Follow-up
Ongoing assessment of disease progression and treatment response is necessary. Risks
Increased risk of anxiety and other psychiatric conditions, particularly in pediatric patients. Patient & Prescribing Data
Patients with alopecia areata in Malaysia, including children and adolescents.
Management strategies are often initiated in primary care settings with potential referrals for specialized care.
Clinical Best Practices
Ensure comprehensive evaluation of disease burden and clinical guidelines adapted to local circumstances. Address psychological impacts and consider mental health consultations for affected patients. Related Resources & Content
